Morningstar Investor users sign in here.

Stocks

Astra and Oxford report strong covid-19 vaccine

Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines.

Mentioned: Moderna Inc (MRNA), BioNTech SE (BNTX), AstraZeneca PLC (AZN), Pfizer Inc (PFE)


Following excellent data from Pfizer/BioNTech and Moderna, AstraZeneca (AZN) and partner Oxford reported favourable phase 3 data on covid-19 vaccine AZD1222. The vaccine has an efficacy rate of 90 per cent (low dose) and 62 per cent (full dose) with no major safety issues observed with the initial data cohort.

At the low dose, the efficacy looks fairly similar to competitor data, albeit slightly lower than the 94 to 95 per cent efficacy reported by others. We are increasing the vaccine’s probability of approval to 90 per cent, but given the firm’s commitment to pricing the vaccine at a non-profit level, we don’t expect any impact to Astra’s fair value estimate. However, the quick development of the vaccine reinforces the firm's innovative power and wide moat.

With the likely authorisation of a third vaccine, we expect global demand will be more easily satisfied over the next few years. Astra expects manufacturing capacity of up to 3 billion doses in 2021. Combined with almost 2 billion doses in total from Pfizer/BioNTech’s and Moderna’s vaccines, close to 3 billion people could be vaccinated (assuming 1.5 to 2 doses for each person).

Also, Astra’s vaccine looks potentially easier to transport with only mild temperature requirements as compared with the other vaccines, which may make Astra’s vaccine more appealing for less developed countries. We expect additional pivotal data from Johnson & Johnson, Sanofi, GlaxoSmithKline and many more vaccine manufacturers in 2021.

We continue to expect the pricing power of the vaccines to be low, especially with several competitors receiving government funding and stating a commitment to low vaccine pricing. However, we expect the very quick development of vaccines to enable the biopharma industry to gain goodwill with governments to help in discussions around any drug pricing reforms.

Morningstar healthcare strategist Karen Anderson delivered a presentation on 'The Race for the Covid-19 Vaccine' at the ' Morningstar Individual Investor Conference. Attendees can view the session here.



© 2023 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This report has been prepared for clients of Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or New Zealand wholesale clients of Morningstar Research Ltd, subsidiaries of Morningstar, Inc. Any general advice has been provided without reference to your financial objectives, situation or needs. For more information refer to our Financial Services Guide at www.morningstar.com.au/s/fsg.pdf. You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782.

More from Morningstar

Are miners attractive after the surge in gold prices?
Stocks

Are miners attractive after the surge in gold prices?

Gold prices are up around 50% in the last two months in anticipation that interest rate increases are coming to an end.
This five-star Aussie stock has a wide moat
Stocks

This five-star Aussie stock has a wide moat

Our analysts believe it can protect and grow its earnings for at least the next 20 years
Despite rally this A-REIT remains undervalued
Stocks

Despite rally this A-REIT remains undervalued

While attractive from a valuation standpoint we do not believe this A-REIT warrants a moat and is highly leveraged.
We advise waiting for a pullback before investing in the world's biggest company
Stocks

We advise waiting for a pullback before investing in the world's biggest company

We’ve raised our fair value estimate and sales forecast, but still see the stock as rich.
7 charts on the AI stock boom one year after ChatGPT’s launch
Stocks

7 charts on the AI stock boom one year after ChatGPT’s launch

These stocks and the key trends behind them are critical for understanding the AI investment landscape.
Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett
Stocks

Why Berkshire Hathaway’s success will continue after Charlie Munger ... and Warren Buffett

Munger’s passing is a spiritual loss for the company.